Initial Phase 1 of 2 RESET-Myositis and RESET-SLE clinical trial data of the investigational therapy, CABA-201, revealed positive outcomes. The first two study participants did not exhibit infections or serious adverse events and complete B cell depletion was observed in both participants after 15 days of treatment. Additionally, at week 4, the SLE study participant demonstrated an improvement in disease activity.
CABA-201 is a CAR T-cell therapy designed to target B cells that is being explored as a possible treatment for systemic lupus erythematosus (SLE) and lupus nephritis (LN, lupus-related kidney disease) . CABA-201 is given as a one-time IV– infusion.
Participants are being recruited for the Phase 1/2 RESET™ trials across 18 sites. Five people have enrolled as of June 12, 2024. Continue to follow the Lupus Foundation of America for CABA-201 updates, as well as other lupus drug development news, and learn about medications used to treat lupus.
This post was originally published on this site